DDDT_A_207955 3009..3019

Bingxuan Niu Hui Zhang Chunyan Li Fulin Yan Yu Song Guangfan Hai Yunjuan Jiao Yansheng Feng 1College of Pharmacy, Xinxiang Medical University, Xingxiang, Henan Province 453003, People’s Republic of China; 2Sanquan College of Xinxiang Medical University, Xinxiang, Henan Province 453002, People’s Republic of China; 3Basic Medical College, Xinxiang Medical University, Xinxiang, Henan Province 453003, People’s Republic of China Objective: The aim of this study was to identify the active anti-ischemic components of Pterocypsela elata (P. elata) using a network pharmacology approach to construct an effective component anti-cerebral ischemic target network and systematically analyze this medicinal material. Methods: Pharmacological studies have shown that P. elata has an obvious effect against cerebral ischemia. To identify the potential targets, 14 components of P. elata were docked to each structural element of the targets in the DRAR-CPI database by reverse docking technology. We then compared the identified potential targets with FDA-approved targets for stroke/cerebral infarction treatment in the DrugBank database and identified the active components of P. elata and their potential targets for stroke/cerebral infarction treatment. The active component-target networks were constructed using Cytoscape 3.5.1 software. The target protein-protein interactions were analyzed using the STRING database. KEGG pathway analysis and gene ontology (GO) enrichment analysis were performed through the Database for Annotation, Visualization and Integrated Discovery (DAVID). Results: There were 14 active components identified from P. elata and 21 potential targets identified for cerebral ischemia treatment, including carbonic anhydrase 2, ribosyldihydronicotinamide dehydrogenase, cholinesterase, and glutathione S-transferase P. The main involved pathways include metabolic pathways, complement and coagulation cascades and steroid hormone biosynthesis. Conclusion: Through a network pharmacology approach, we predicted the active components of P. elata and their potential targets for cerebral ischemia treatment. Our results provide new perspectives and clues for further studies on the anti-cerebral ischemia mechanism of P. elata.

[1]  Qinghai Huang,et al.  Recent advances in the development of neuroprotective agents and therapeutic targets in the treatment of cerebral ischemia. , 2019, European journal of medicinal chemistry.

[2]  Liuting Zeng,et al.  Exploring the Pharmacological Mechanism of Danzhi Xiaoyao Powder on ER-Positive Breast Cancer by a Network Pharmacology Approach , 2018, Evidence-based complementary and alternative medicine : eCAM.

[3]  Xiong-Zhi Wu,et al.  Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients , 2017, Oncotarget.

[4]  M. Ramanathan,et al.  Activation of AKT1/GSK-3β/β-Catenin–TRIM11/Survivin Pathway by Novel GSK-3β Inhibitor Promotes Neuron Cell Survival: Study in Differentiated SH-SY5Y Cells in OGD Model , 2016, Molecular Neurobiology.

[5]  Chang-ik Choi,et al.  Antioxidant and α-glucosidase inhibitory phenolic constituents of Lactuca indica L. , 2016, Russian Journal of Bioorganic Chemistry.

[6]  Yong Wang,et al.  BATMAN-TCM: a Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine , 2016, Scientific Reports.

[7]  Thomas J. Anastasio,et al.  Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease , 2015, Front. Pharmacol..

[8]  Fu‐Lin Yan,et al.  A New Guaianolide (I) and Other Constituents from Pterocypsela elata , 2014 .

[9]  Peter Jüni,et al.  Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis , 2012, Annals of the rheumatic diseases.

[10]  B. Niu,et al.  [Effect of lactuside B on the expression of bcl-2 and bax mRNA and their protein in rats' cerebral cortex after cerebral ischemia-reperfusion injury]. , 2011, Yao xue xue bao = Acta pharmaceutica Sinica.

[11]  R. Giffard,et al.  Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury , 2004, Experimental Neurology.

[12]  Steven C. R. Williams,et al.  The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques , 2003, Brain Research.

[13]  J. Herbert,et al.  Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone‐induced suppression , 2002, The European journal of neuroscience.

[14]  J. Poirier,et al.  Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. , 1999, Brain research. Molecular brain research.

[15]  Jiansong Fang,et al.  Network pharmacology-based analysis of Chinese herbal Naodesheng formula for application to Alzheimer's disease. , 2018, Chinese journal of natural medicines.

[16]  Bei Sun,et al.  Network Pharmacological Screening of Herbal Monomers that Regulate Apoptosis-Associated Genes in Acute Pancreatitis , 2017, Pancreas.

[17]  J. Yang,et al.  Influence of lactuside B on the expression of AQP4 and TRPM7 mRNAs in the cerebral cortex after cerebral ischemia injury. , 2014, European review for medical and pharmacological sciences.

[18]  Yili Bai,et al.  A new guaianolide from the roots of Pterocypsela elata , 2013 .

[19]  P. Petkow-Dimitrow.  [New therapeutic targets for ACE inhibitors and angiotensin receptor blockers]. , 2007, Polskie Archiwum Medycyny Wewnetrznej.

[20]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.